Filtered By:
Drug: Fortamet

This page shows you your search results in order of relevance. This is page number 10.

Order by Relevance | Date

Total 9822 results found since Jan 2013.

Increased Risk of Cognitive Impairment in Patients With Diabetes Is Associated With Metformin.
CONCLUSIONSMetformin use was associated with impaired cognitive performance. Vitamin B12 and calcium supplements may alleviate metformin-induced vitamin B12 deficiency and were associated with better cognitive outcomes. Prospective trials are warranted to assess the beneficial effects of vitamin B12 and calcium use on cognition in older people with diabetes who are taking metformin. PMID: 24009301 [PubMed - as supplied by publisher]
Source: Diabetes Care - September 5, 2013 Category: Endocrinology Authors: Moore EM, Mander AG, Ames D, Kotowicz MA, Carne RP, Brodaty H, Woodward M, Boundy K, Ellis KA, Bush AI, Faux NG, Martins R, Szoeke C, Rowe C, Watters DA, the AIBL Investigators Tags: Diabetes Care Source Type: research

Correlates of Treatment Patterns among Youth with Type 2 Diabetes.
ConclusionsAbout half of youth with type 2 diabetes were managed with lifestyle or metformin alone, and had better glycemic control than individuals using other therapies. Those with longer diabetes duration in particular commonly experience treatment failures and more effective management strategies are needed. PMID: 24026554 [PubMed - as supplied by publisher]
Source: Diabetes Care - September 11, 2013 Category: Endocrinology Authors: Badaru A, Klingensmith GJ, Dabelea D, Mayer-Davis EJ, Dolan L, Lawrence JM, Marcovina S, Beavers D, Rodriguez BL, Imperatore G, Pihoker C Tags: Diabetes Care Source Type: research

Feasibility of closed-loop insulin delivery in type 2 diabetes: a randomised controlled study.
ConclusionsA closed-loop system without meal announcement using subcutaneous insulin delivery in insulin-naïve type 2 diabetes appears feasible and safe. Improvement in postprandial glucose control may require further optimisation of system performance. PMID: 24026542 [PubMed - as supplied by publisher]
Source: Diabetes Care - September 11, 2013 Category: Endocrinology Authors: Kumareswaran K, Thabit H, Leelarathna L, Caldwell K, Elleri D, Allen JM, Nodale M, E Wilinska M, L Evans M, Hovorka R Tags: Diabetes Care Source Type: research

Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes: A >=52-week randomized, double-blind study.
CONCLUSIONSLinagliptin added to basal insulin therapy significantly improved glycemic control relative to placebo without increasing hypoglycemia or body weight. PMID: 24062327 [PubMed - as supplied by publisher]
Source: Diabetes Care - September 23, 2013 Category: Endocrinology Authors: Yki-Järvinen H, Rosenstock J, Durán-Garcia S, Pinnetti S, Bhattacharya S, Thiemann S, Patel S, Woerle HJ Tags: Diabetes Care Source Type: research

Association of Hypoglycemic Treatment Regimens on Cardiovascular Outcomes in Overweight and Obese Subjects With Type 2 Diabetes: A Substudy of the SCOUT Trial.
CONCLUSIONSIn obese patients with type 2 diabetes and high risk of cardiovascular disease, monotherapy with metformin or diet-only treatment were associated with lower risk of cardiovascular events than treatment with insulin. PMID: 24089540 [PubMed - as supplied by publisher]
Source: Diabetes Care - October 2, 2013 Category: Endocrinology Authors: Ghotbi AA, Køber L, Finer N, James WP, Sharma AM, Caterson I, Coutinho W, Van Gaal LF, Torp-Pedersen C, Andersson C Tags: Diabetes Care Source Type: research

Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Studys.
CONCLUSIONS-These results suggest that in patients with type 2 diabetes, inadequately controlled on sitagliptin with or without metformin, add-on treatment with dapagliflozin provides additional clinical benefit and is well tolerated. PMID: 24144654 [PubMed - as supplied by publisher]
Source: Diabetes Care - October 21, 2013 Category: Endocrinology Authors: Jabbour SA, Hardy E, Sugg J, Parikh S, for the Study 10 Group Tags: Diabetes Care Source Type: research

Metformin, but not rosiglitazone, attenuates the increasing plasma levels of a new cardiovascular marker, fibulin-1, in patients with type 2 diabetes.
ConclusionsMetformin attenuate the increase in plasma fibulin-1 concentrations in type 2 diabetes, independently of glycemic effects. Changes in fibulin-1 may reflect an important element in diabetic arteriopathy which can be influenced by metformin. PMID: 24135389 [PubMed - as supplied by publisher]
Source: Diabetes Care - October 17, 2013 Category: Endocrinology Authors: Skov V, Cangemi C, Gram J, Christensen MM, Grodum E, Sørensen D, Argraves WS, Henriksen JE, Rasmussen LM Tags: Diabetes Care Source Type: research

Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin: An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes.
CONCLUSIONSLong-term empagliflozin treatment provided sustained glycemic and weight control and was well tolerated with a low risk of hypoglycemia in patients with type 2 diabetes. PMID: 24186878 [PubMed - as supplied by publisher]
Source: Diabetes Care - November 1, 2013 Category: Endocrinology Authors: Ferrannini E, Berk A, Hantel S, Pinnetti S, Hach T, Woerle HJ, Broedl UC Tags: Diabetes Care Source Type: research

Profiling of Circulating MicroRNAs Reveals Common MicroRNAs Linked to Type 2 Diabetes That Change With Insulin Sensitization.
CONCLUSIONSThis study depicts the close association between variations in circulating miRNAs and T2D and their potential relevance in insulin sensitivity. PMID: 24478399 [PubMed - as supplied by publisher]
Source: Diabetes Care - January 29, 2014 Category: Endocrinology Authors: Ortega FJ, Mercader JM, Moreno-Navarrete JM, Rovira O, Guerra E, Esteve E, Xifra G, Martínez C, Ricart W, Rieusset J, Rome S, Karczewska-Kupczewska M, Straczkowski M, Fernández-Real JM Tags: Diabetes Care Source Type: research

Metformin causing vitamin B12 deficiency: a guilty verdict without sufficient evidence.
PMID: 24459156 [PubMed - in process]
Source: Diabetes Care - February 1, 2014 Category: Endocrinology Authors: Obeid R Tags: Diabetes Care Source Type: research

Incidence of Bladder Cancer in Patients With Type 2 Diabetes Treated With Metformin or Sulfonylureas.
CONCLUSIONUse of metformin is not associated with a decreased incidence of bladder cancer. Similar methods should be used to study other cancers that have previously been identified as potentially preventable with metformin. PMID: 24496803 [PubMed - as supplied by publisher]
Source: Diabetes Care - February 4, 2014 Category: Endocrinology Authors: Mamtani R, Pfanzelter N, Haynes K, Finkelman BS, Wang X, Keefe SM, Haas NB, Vaughn DJ, Lewis JD Tags: Diabetes Care Source Type: research

Use of Antidiabetic Drugs in the U.S., 2003-2012.
CONCLUSIONSThe antidiabetic drug market is characterized by steady increases in volume, and newly approved drugs experienced substantial uptake, especially DPP-4 inhibitors. The use of rosiglitazone has been negligible since restrictions were put in place in 2011. Further study is needed to understand why one-third to one-half of other noninsulin antidiabetic drug use was not concomitant with metformin use despite guidelines recommending that metformin be continued when other agents are added to treatment. PMID: 24623020 [PubMed - as supplied by publisher]
Source: Diabetes Care - March 12, 2014 Category: Endocrinology Authors: Hampp C, Borders-Hemphill V, Moeny DG, Wysowski DK Tags: Diabetes Care Source Type: research

Can a Selective PPARγ Modulator Improve Glycemic Control in Patients With Type 2 Diabetes With Fewer Side Effects Compared With Pioglitazone?
CONCLUSIONSINT131 demonstrated dose-dependent reductions in HbA1c, equivalent to 45 mg pioglitazone, but with less fluid accumulation and weight gain, consistent with its SPPARM design. PMID: 24722496 [PubMed - as supplied by publisher]
Source: Diabetes Care - April 10, 2014 Category: Endocrinology Authors: Depaoli AM, Higgins LS, Henry RR, Mantzoros C, Dunn FL, for the INT131-007 Study Group Tags: Diabetes Care Source Type: research

Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
CONCLUSIONSEmpagliflozin 10 and 25 mg for 24 weeks as add-on to metformin therapy significantly improved glycemic control, weight, and BP, and were well-tolerated. PMID: 24722494 [PubMed - as supplied by publisher]
Source: Diabetes Care - April 10, 2014 Category: Endocrinology Authors: Häring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Broedl UC, Woerle HJ, for the EMPA-REG MET Trial Investigators Tags: Diabetes Care Source Type: research

Lifestyle and Metformin Interventions Have a Durable Effect to Lower CRP and tPA Levels in the Diabetes Prevention Program Except in Those Who Develop Diabetes.
CONCLUSIONS: Lifestyle and metformin interventions have durable effects to lower hs-CRP and tPA. Incident diabetes prevented these improvements, and this was accounted for by differences in weight, insulin resistance, and glucose levels. PMID: 24824548 [PubMed - as supplied by publisher]
Source: Diabetes Care - May 13, 2014 Category: Endocrinology Authors: Goldberg RB, Temprosa MG, Mather KJ, Orchard TJ, Kitabchi AE, Watson KE, for the Diabetes Prevention Program Research Group* Tags: Diabetes Care Source Type: research